Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;14(7):264-272.
doi: 10.14740/jocmr4676. Epub 2022 Jul 29.

Kidney Replacement Therapy in Cardiorenal Syndromes

Affiliations
Review

Kidney Replacement Therapy in Cardiorenal Syndromes

Daniel Patschan et al. J Clin Med Res. 2022 Jul.

Abstract

Cardiorenal syndromes (CRS) have increasingly been recognized as distinct disorders that affect the heart and kidneys simultaneously, either with acute or chronic onset. The different types share common pathophysiological characteristics. The concept "cardiorenal" shall emphasize the inter- or even multidisciplinary approach to respective patients. Anticongestive therapy becomes mandatory in many subjects that suffer from CRS. In recent years, the role of dialysis treatment in a broader sense has been investigated in CRS in more detail. We performed a search for studies related to the topic in the following databases: MEDLINE, PROSPERO, and Web of Science. The following keywords were used for reference identification: "CRS", "cardiorenal syndrome", "dialysis", "hemodialysis", "hemofiltration", "renal replacement therapy", "kidney replacement therapy", "peritoneal dialysis", and "aquapheresis". Finally, a total number of 22 studies, partly performed as retrospective cohort studies, and partly designed as prospective investigations, were included. The selected studies evaluated different modes of peritoneal dialysis (PD) or of non-PD procedures including intermittent hemodialysis, continuous procedures, and so-called aquapheresis. Inclusion and outcome parameters were almost not comparable between selected trials. Some studies revealed dialysis as effective, with reasonable tolerability. Particularly so-called "pure" ultrafiltration (e.g., aquapheresis) was associated with higher rates of adverse events. Future studies should be designed in a more homogenous manner, particularly concerning the inclusion criteria, the respective dialysis procedure applied, and endpoints in the short- and long-term.

Keywords: Cardiorenal syndrome; Kidney replacement therapy; Peritoneal dialysis; Refractory hypervolemia; Ultrafiltration.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflict of interest to disclose.

References

    1. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527–1539. doi: 10.1016/j.jacc.2008.07.051. - DOI - PubMed
    1. Lewis T. A clinical lecture on paroxysmal dyspnoea in cardiorenal patients: with special reference to "cardiac" and "uraemic" asthma: delivered at University College Hospital, London, November 12th, 1913. Br Med J. 1913;2(2761):1417–1420. doi: 10.1136/bmj.2.2761.1417. - DOI - PMC - PubMed
    1. Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K. Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol. 2013;9(2):99–111. doi: 10.1038/nrneph.2012.279. - DOI - PubMed
    1. Pavo N, Yarragudi R, Puttinger H, Arfsten H, Strunk G, Bojic A, Hulsmann M. et al. Parameters associated with therapeutic response using peritoneal dialysis for therapy refractory heart failure and congestive right ventricular dysfunction. PLoS One. 2018;13(11):e0206830. doi: 10.1371/journal.pone.0206830. - DOI - PMC - PubMed
    1. Ponce D, Goes C, Oliveira M, Balbi A. Peritoneal dialysis for the treatment of cardiorenal syndrome type 1: a prospective Brazilian study. Perit Dial Int. 2017;37(5):578–583. doi: 10.3747/pdi.2016.00217. - DOI - PubMed

LinkOut - more resources